hypoxia-inducible factor-1 alpha is a key regulator of angiogenesis and inflammation in rheumatoid arthritis: a case-control study

注册号:

Registration number:

ITMCTR1900002659

最近更新日期:

Date of Last Refreshed on:

2019-10-11

注册时间:

Date of Registration:

2019-10-11

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

缺氧诱导因子-1α—是类风湿关节炎患者中血管翳生成和产生炎症的关键调节因子:病例对照研究

Public title:

hypoxia-inducible factor-1 alpha is a key regulator of angiogenesis and inflammation in rheumatoid arthritis: a case-control study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

缺氧诱导因子-1α—是类风湿关节炎患者中血管翳生成和产生炎症的关键调节因子:病例对照研究

Scientific title:

hypoxia-inducible factor-1 alpha is a key regulator of angiogenesis and inflammation in rheumatoid arthritis: a case-control study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900026471 ; ChiMCTR1900002659

申请注册联系人:

郑林

研究负责人:

肖涟波

Applicant:

Zheng Lin

Study leader:

Xiao Lianbo

申请注册联系人电话:

Applicant telephone:

+86 15221199296

研究负责人电话:

Study leader's telephone:

021-62805833

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhenglin0705@163.cpm

研究负责人电子邮件:

Study leader's E-mail:

13701888178@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市新华路540号

研究负责人通讯地址:

上海市新华路540号

Applicant address:

540 Xinhua Road, Shanghai, China

Study leader's address:

540 Xinhua Road, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

200052

研究负责人邮政编码:

Study leader's postcode:

200052

申请人所在单位:

上海中医药大学附属光华医院

Applicant's institution:

Shanghai Traditional Medicine University Affiliated Guanghua Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

AF13v2-2

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

上海光华中西医结合医院伦理委员会

Name of the ethic committee:

Shanghai Guanghua Integrated Chinese and Western Medicine Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2018/11/13 0:00:00

伦理委员会联系人:

李丹

Contact Name of the ethic committee:

Shanghai Guanghua Integrated Chinese and Western Medicine Hospital Ethics Committee

伦理委员会联系地址:

上海市新华路540号

Contact Address of the ethic committee:

540 Xinhua Road, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海中医药大学附属光华医院

Primary sponsor:

Shanghai Traditional Medicine University Affiliated Guanghua Hospital

研究实施负责(组长)单位地址:

上海市新华路540号

Primary sponsor's address:

540 Xinhua Road, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属光华医院

具体地址:

上海市新华路540号

Institution
hospital:

Shanghai Traditional Medicine University Affiliated Guanghua Hospital

Address:

540 Xinhua Road, Shanghai

经费或物资来源:

上海市科学技术委员会

Source(s) of funding:

Shanghai Science and Technology Commission

研究疾病:

类风湿关节炎

研究疾病代码:

Target disease:

Rheumatoid Arthritis

Target disease code:

研究类型:

Study type:

基础科学研究

Basic Science

研究设计:

Study design:

析因分组(即根据危险因素或暴露因素分组)

Factorial

研究所处阶段:

Study phase:

其它

Others

研究目的:

探讨缺氧诱导因子(HIF-1α)及其下游因子诱导型一氧化氮合酶(INOS)、血管内皮生长因子A(VEGFA)在类风湿关节炎中滑膜增生中的作用,进一步研究其抑制滑膜大量增生的可能途径与机制.

Objectives of Study:

To investigate the role of hypoxia inducible factor (hif-1 a) and its downstream inducible nitric oxide synthase (INOS) and vascular endothelial growth factor (VEGF) in synovial hyperplasia in rheumatoid arthritis, and to further investigate the possible pathway and mechanism of inhibiting synovial hyperplasia.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

RA入组标准: (1)明确诊断为类风湿关节炎 (2) 无心、脑血管、肝、肾和造血系统等严重原发性疾病、慢性消耗性疾病及精神病患者; (3)患者膝关节疼痛伴有破坏,需要行膝关节置换术病人。 (4) 患者依从性较好,能完成整个疗程。

Inclusion criteria

Criteria for RA: (1) patients with definite diagnosis of rheumatoid arthritis; (2) patients have no serious primary diseases, chronic wasting diseases and mental disorders such as cardiac, cerebrovascular, liver, kidney and hematopoietic system; (3) patients with knee joint pain accompanied by destruction need knee joint replacement; (4) patients have better compliance and can complete the whole course of treatment.

排除标准:

(1) 患者拒绝行膝关节置换术。 (2) 患有手术禁忌症 (3)依从性差者或正在参加其他药物试验者。 (4)未按规定用本试验方案治疗的病例。

Exclusion criteria:

(1) the patients refused to undergo knee replacement; (2) the patients have surgical contraindications; (3) those with poor compliance or who are participating in other drug trials; (4) patients who have not been treated with this test protocol as required.

研究实施时间:

Study execute time:

From 2019-10-07

To      2020-03-15

征募观察对象时间:

Recruiting time:

From 2019-10-07

To      2020-03-10

干预措施:

Interventions:

组别:

类风湿关节炎组

样本量:

14

Group:

Rheumatoid arthritis group

Sample size:

干预措施:

Ni

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

骨关节炎组

样本量:

14

Group:

Osteoarthritis group

Sample size:

干预措施:

Nil

干预措施代码:

Intervention:

Nil

Intervention code:

样本总量 Total sample size : 28

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属光华医院

单位级别:

三甲医院

Institution/hospital:

Shanghai Traditional Medicine University Affiliated Guanghua Hospital

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

血管内皮生长因子A

指标类型:

主要指标

Outcome:

VEGFA

Type:

Primary indicator

测量时间点:

手术后

测量方法:

聚合酶联锁反应

Measure time point of outcome:

After the operation

Measure method:

PCR

指标中文名:

诱导型一氧化氮合酶

指标类型:

主要指标

Outcome:

INOS

Type:

Primary indicator

测量时间点:

手术后

测量方法:

聚合酶联锁反应

Measure time point of outcome:

After the operation

Measure method:

PCR

指标中文名:

缺氧诱导因子-1α

指标类型:

主要指标

Outcome:

HIF-1 alpha

Type:

Primary indicator

测量时间点:

手术后

测量方法:

聚合酶联锁反应

Measure time point of outcome:

After the operation

Measure method:

PCR

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

膝关节滑膜组织

组织:

Sample Name:

Synovial tissue of knee joint

Tissue:

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 60
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

本实验市病例对照研究,无需随机方法

Randomization Procedure (please state who generates the random number sequence and by what method):

This is a case-control study without the need for a randomized method

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2020.03.20公布数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2020.03.20sharing IPD

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例收集表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case collection table

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above